One Step Closer to the Artificial Pancreas

Ever since pressure began to increase last year to develop an artificial pancreas for treating Type 1 diabetes, periodic reports have indicated that the project is making progress. For example, a few months ago Medtronic reported that the ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study met its efficacy endpoints. The study revealed that patients using the MiniMed Paradigm system featuring Low Glucose Suspend automation showed a 19% reduction in time spent below the low-glucose threshold, compared with conventional pump therapy

Now, results from the first feasibility study of an advanced first-generation artificial pancreas system indicate that the system was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely. Conducted by Animas Corp. (West Chester, PA) in collaboration with JDRF (New York City) as part of an ongoing partnership to advance the development of a closed-loop artificial pancreas system for patients with Type 1 diabetes, the study focused on the hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin pump; a continuous glucose monitor; and software used to predict changes in blood glucose.

"The successful completion of this study using the HHM System in a human clinical trial setting is a significant step forward in the development of an advanced first-generation artificial pancreas system," notes Henry Anhalt, Animas's chief medical officer and medical director of the artificial pancreas program. "It lays the foundation for subsequent clinical trials, bringing us one step closer to making the dream of an artificial pancreas a reality for millions of people living with Type 1 diabetes."

JDRF, a global leader in type 1 diabetes(T1D) research, announced that an outpatient study being conducted at multiple academic institutions has demonstrated the safety and feasibility of artificial pancreas (AP) device testing on an ambulatory basis. The research, funded by JDRF, was presented this weekend at the 72nd American Diabetes Association (ADA) Scientific Sessions.

Source: PR Newswire (http://s.tt/1e5K2)

JDRF, a global leader in type 1 diabetes(T1D) research, is pleased to announce that an outpatient study being conducted at multiple academic institutions has demonstrated the safety and feasibility of artificial pancreas (AP) device testing on an ambulatory basis. The research, funded by JDRF, was presented this weekend at the 72nd American Diabetes Association (ADA) Scientific Sessions.

Source: PR Newswire (http://s.tt/1e5K2)

For more information on the artificial pancreas, check out these stories: